January 16, 2025
Thyroid Vol 35, No. 1
This research article investigates the potential link between glucagon-like peptide 1 receptor agonists (GLP1-RAs), medications used for type 2 diabetes, and the risk of developing thyroid cancer. Conducted as a large, international study across multiple sites in six countries, it compared GLP1-RA users with those using dipeptidyl peptidase-4 inhibitors (DPP-4is), another class of diabetes drugs. Analyzing a substantial number of patients, the study found no increased risk of thyroid cancer associated with GLP1-RA use during the observed follow-up period. Furthermore, increasing cumulative doses of GLP1-RAs did not show an increased risk, although the authors acknowledge that the relatively short follow-up duration limits conclusions about long-term effects. Supplementary analyses generally supported these findings, providing reassurance regarding the short-term safety of these medications concerning thyroid cancer.
Audio Overview (Google NotebookLM)
(17 minutes 00 seconds)
